CSO & EVP, Head of Research · ALNYLAM PHARMACEUTICALS, INC. · Common Stock
Side
SELL
Value
$34K
Shares
96
Price
$357.17
Executed
Jan 12, 2026
Disclosed
Jan 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 12 executedJan 14, 2026 disclosed
ALNY · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+15 / 15
4 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Fitzgerald Kevin Joseph filed this Form 4 reporting a open-market sale of ALNY on Jan 12, 2026. It became public on Jan 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CSO & EVP, Head of Research
Fitzgerald Kevin Josephcik:0001886431
Issuer
ALNYLAM PHARMACEUTICALS, INC.cik:0001178670
Revision history · 0
No field has changed since this record was first ingested.
